Rank #1918ESPR

Esperion Therapeutics, Inc.

$3.52

-1.40% (Daily)

Market Cap

$841.50M

Revenue

$303.80M

Rank by MCap

#1918

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Sheldon L. Koenig M.B.A.

Headquarters

Ann Arbor, MI

Employees

304

About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiov...